Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The company said the decision to start advanced injectable therapy is often delayed in many patients due to cost and complexity. With GLIPIQ, Glenmark aims to improve affordability and enable earlier treatment initiation across a broader patient population.

GLIPIQ has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India. The study demonstrated favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.

The drug is available in both vial and pre-filled pen formulations. The vial-based version, supported by dose-specific syringes, is designed to allow flexible, physician-guided dosing, particularly during the early stages of therapy. The company said this format is expected to offer a more cost-effective treatment option, with weekly therapy priced between Rs 325 and Rs 440.

The pre-filled pen formulation offers the convenience of self-dosing for long-term use. Together, the two formats are intended to provide a structured treatment pathway that supports adherence, continuity of care, and improved patient outcomes.

Alongside the product launch, Glenmark has introduced a patient support programme named ?Sankalp?, aimed at assisting therapy initiation, improving comfort with injectable treatments, and supporting long-term adherence.

Semaglutide, a GLP-1 receptor agonist, is widely used in the management of Type 2 diabetes, particularly in patients with comorbidities such as obesity, cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease, due to its broader cardiometabolic benefits beyond glycaemic control.

Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals, said, ?Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs 325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.

Building on our experience in the GLP-1 category, including Lirafit? (Liraglutide), and supported by our ?Sankalp? program, we aim to help more patients access, initiate, and continue therapy over time.?

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.

Shares of Glenmark Pharmaceuticals rallied 3.94% to Rs 2,181.05 on the BSE.

Powered by Capital Market - Live News

The product has been deemed bioequivalent to Flonase Allergy Relief Nasal Spray, marketed by Haleon US Holding LLC. The approved spray will be distributed in the US by Glenmark Therapeutics Inc., USA.

According to Nielsen syndicated data for the 52-week period ended March 3, 2026, the Flonase Allergy Relief Nasal Spray market recorded annual sales of approximately $384.7 million, indicating a sizeable opportunity for Glenmark in the OTC segment.

Marc Kikuchi, President & Business Head, North America, said, ?We are excited to announce the recent approval of Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). As the first approved nasal spray distributed by Glenmark Therapeutics Inc., USA in the OTC space, we look forward to bringing this quality over-thecounter solution to our customers when we launch in April 2026.?

Separately, Glenmark Pharmaceuticals Inc., USA also announced the launch of Milnacipran Hydrochloride Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg. The product is the authorized generic version of Savella Tablets.

As per IQVIA sales data for the 12-month period ending January 2026, the Savella tablets market generated annual sales of around $102.9 million.

Marc Kikuchi, President & Business Head, North America said, ?We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella? Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.?

The dual developments underline Glenmark?s strategic push to strengthen its presence across both OTC and prescription segments in North America.

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.

Shares of Glenmark Pharmaceuticals declined 2.03% to Rs 2,142.10 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella?2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIA sales data for the 12-month period ending January 2026, the Savella? Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million.

Powered by Capital Market - Live News

The injection will be available in 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials.

The product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi. Distribution is expected to begin in March 2026.

According to sales data from IQVIA, the Potassium Phosphates Injection market in the US recorded annual sales of about $50.7 million for the 12-month period ended January 2026.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, ?We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch.?

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals, the company, reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News